Syngene International Limited SYNGENE NIFTY_SMALLNSEPHARMA
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 56.2.
- Earnings shrank at -12.0% CAGR over 5 years.
- Trading 38.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SYNGENE Syngene International Limited NIFTY_SMALLNSEPHARMA | 442.00 | 56.16 | ₹17,761.82 Cr | 0.28% | 8.35% | 6.62% | 6.67% | -11.98% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 943.70 Cr | 1,018.00 Cr | 874.50 Cr | 917.10 Cr | 1,036.50 Cr |
| Cost of Revenue | 237.40 Cr | 235.00 Cr | 217.60 Cr | 229.40 Cr | 233.10 Cr |
| Gross Profit | 706.30 Cr | 783.00 Cr | 656.90 Cr | 687.70 Cr | 803.40 Cr |
| Operating Expenses | 533.10 Cr | 540.90 Cr | 556.90 Cr | 569.00 Cr | 590.40 Cr |
| Operating Income | 173.20 Cr | 242.10 Cr | 100.00 Cr | 118.70 Cr | 213.00 Cr |
| EBITDA | 301.90 Cr | 362.50 Cr | 224.10 Cr | 154.00 Cr | 319.60 Cr |
| Interest Expense | 12.40 Cr | 15.90 Cr | 11.60 Cr | 11.90 Cr | 12.10 Cr |
| Pretax Income | 180.80 Cr | 240.50 Cr | 101.30 Cr | 28.40 Cr | 196.00 Cr |
| Tax Provision | 49.70 Cr | 57.20 Cr | 14.60 Cr | 13.40 Cr | 48.10 Cr |
| Net Income | 131.10 Cr | 183.30 Cr | 86.70 Cr | 15.00 Cr | 147.90 Cr |
| Diluted EPS | 3.26 | 4.56 | 2.15 | 0.37 | 3.67 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 3,080.20 Cr | 3,369.50 Cr | 3,642.40 Cr | 3,738.70 Cr |
| Cost of Revenue | - | 860.20 Cr | 930.20 Cr | 942.50 Cr | 918.60 Cr |
| Gross Profit | - | 2,220.00 Cr | 2,439.30 Cr | 2,699.90 Cr | 2,820.10 Cr |
| Operating Expenses | - | 1,601.80 Cr | 1,792.20 Cr | 2,088.80 Cr | 2,293.60 Cr |
| Operating Income | - | 618.20 Cr | 647.10 Cr | 611.10 Cr | 526.50 Cr |
| EBITDA | - | 994.60 Cr | 1,091.80 Cr | 1,145.60 Cr | 912.60 Cr |
| Interest Expense | - | 34.50 Cr | 45.10 Cr | 53.10 Cr | 48.80 Cr |
| Pretax Income | - | 593.60 Cr | 620.80 Cr | 659.90 Cr | 410.90 Cr |
| Tax Provision | - | 129.20 Cr | 110.80 Cr | 163.70 Cr | 94.20 Cr |
| Net Income | - | 464.40 Cr | 510.00 Cr | 496.20 Cr | 316.70 Cr |
| Diluted EPS | 9.82 | 11.51 | 12.69 | 12.34 | - |
Compounded Sales Growth
| 5 Years: | 6.67% |
| 1 Year: | 1.80% |
Compounded Profit Growth
| 5 Years: | -11.98% |
| 1 Year: | -19.50% |
Stock Price Performance
| 1 Year: | -31.63% |
| 6 Months: | -30.91% |
| 3 Months: | -1.11% |
| 1 Month: | +2.28% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 5,831.00 Cr | 6,151.60 Cr | 6,795.90 Cr | 7,054.70 Cr |
| Current Assets | - | 2,425.30 Cr | 1,959.00 Cr | 2,287.30 Cr | 2,142.80 Cr |
| Cash & Equivalents | - | 87.00 Cr | 85.60 Cr | 366.90 Cr | 228.60 Cr |
| Inventory | - | 332.80 Cr | 238.50 Cr | 155.50 Cr | 141.30 Cr |
| Receivables | - | 529.30 Cr | 441.60 Cr | 526.80 Cr | 508.80 Cr |
| Total Liabilities | - | 2,213.00 Cr | 1,893.90 Cr | 2,069.10 Cr | 2,215.60 Cr |
| Current Liabilities | - | 1,188.20 Cr | 1,144.30 Cr | 1,396.40 Cr | 1,552.30 Cr |
| Long Term Debt | 531.50 Cr | 489.00 Cr | 100.00 Cr | 0 | - |
| Total Debt | - | 815.20 Cr | 555.20 Cr | 577.90 Cr | 458.40 Cr |
| Total Equity | - | 3,618.00 Cr | 4,257.70 Cr | 4,726.80 Cr | 4,839.10 Cr |
| Shares Outstanding | - | 40.14 Cr | 40.20 Cr | 40.25 Cr | 40.29 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 823.50 Cr | 1,042.10 Cr | 1,167.60 Cr | 915.20 Cr |
| Investing Cash Flow | - | -656.40 Cr | -495.60 Cr | -744.70 Cr | -860.40 Cr |
| Financing Cash Flow | - | -342.50 Cr | -551.40 Cr | -141.80 Cr | -215.00 Cr |
| Capital Expenditure | - | -518.30 Cr | -510.80 Cr | -770.10 Cr | -368.20 Cr |
| Free Cash Flow | - | 305.20 Cr | 531.30 Cr | 397.50 Cr | 547.00 Cr |
| Net Change in Cash | - | -175.40 Cr | -4.90 Cr | 281.10 Cr | -160.20 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 72.1% | 72.4% | 74.1% | 75.4% |
| Operating Margin % | - | 20.1% | 19.2% | 16.8% | 14.1% |
| Net Margin % | - | 15.1% | 15.1% | 13.6% | 8.5% |
| ROE % | - | 12.8% | 12.0% | 10.5% | 6.5% |
| ROCE % | - | 13.3% | 12.9% | 11.3% | 9.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SYNGENE